AUG 10, 2021 7:00 AM PDT

A Tapeworm Drug as a COVID Antiviral?

WRITTEN BY: Tara Fernandes

A study by researchers at the Scripps Research Institute looking into potential COVID-19 medications has revealed a surprising lead candidate: a drug currently used to treat tapeworm infections. The compound was shown to not only dampen inflammation but block the proliferation of SARS-CoV-2, making it a promising potential therapeutic to treat severe cases of COVID-19.

Tapeworms are flat, segmented parasites that live in the intestines of animals. These worms can be transmitted to humans by eating undercooked meat but are easily treated with a class of small molecules called salicylanilides.

Interestingly, salicylanilides have also been known to have potent antiviral effects, which led researchers to hypothesize that they may repurpose them to treat COVID-19. The problem, however, is that salicylanilides are typically restricted to treating gut-related infections, and, to make matters worse, high doses of the drugs are known to be toxic.

To overcome these barriers, a team of scientists led by Kim Janda screened a panel of 60 modified salicylanilide molecules in rodents before identifying one compound with a low toxicity profile that was readily absorbed into the bloodstream from the digestive tract.

Janda and colleagues found two critical features of this compound that make it an attractive option for treating COVID-19—it disrupts the mechanism by which the coronavirus deposits its genetic material into human cells, and it calms inflammation by reducing levels of an inflammatory cytokine called interleukin-6.

“The combination of anti-SARS-CoV-2 activity, cytokine inhibitory activity, and a previously established favorable pharmacokinetic profile for the lead salicylanilide render salicylanilides in general as promising therapeutics for COVID-19,” wrote the authors.

 



Source: ACS Infectious Diseases.

About the Author
PhD
Interested in health technology and innovation.
You May Also Like
JUN 06, 2022
Health & Medicine
Stagnant US Cervical Cancer Survival Rates
JUN 06, 2022
Stagnant US Cervical Cancer Survival Rates
According to JAMA Network, despite the overall cancer mortality rate decreasing since the 90s, cervical cancer survival ...
JUN 14, 2022
Coronavirus
Advances in Latest Coronavirus Research in the 2022 Ongoing Labroots Virtual Event Series
JUN 14, 2022
Advances in Latest Coronavirus Research in the 2022 Ongoing Labroots Virtual Event Series
Labroots hosted its 3rd annual Coronavirus Conference Virtual Event Series on May 4, 2022. The speaker roster for this f ...
JUN 15, 2022
Drug Discovery & Development
High Intensity Ultrasound Therapy Treats Localized Prostate Cancer
JUN 15, 2022
High Intensity Ultrasound Therapy Treats Localized Prostate Cancer
High-intensity-focused ultrasound (HIFU) can treat some men with prostate cancer instead of surgery or radiation therapy ...
JUN 23, 2022
Clinical & Molecular DX
Accelerate diagnostic development with the right supplier
JUN 23, 2022
Accelerate diagnostic development with the right supplier
Diagnostic assays like the one you’re developing are in demand. But your task isn’t simple. Set yourself up ...
JUL 15, 2022
Immunology
Pox Virus Proteins Can Launch Early Attack on Immune Defense
JUL 15, 2022
Pox Virus Proteins Can Launch Early Attack on Immune Defense
After a virus gets inside of a cell, it typically takes over the cell to produce more viral particles. But pox viruses g ...
AUG 07, 2022
Drug Discovery & Development
Monoclonal Antibody Treatment Shows Promise in Preventing Malaria
AUG 07, 2022
Monoclonal Antibody Treatment Shows Promise in Preventing Malaria
A singular injection of a monoclonal antibody treatment candidate has been shown as safe and highly protective in US adu ...
Loading Comments...